Sign In
Buy ITCI
$131.87
+0 (+0%)
At Close: Jul 01, 2025
Recap: Intra-Cellular Therapies Q1 Earnings
08:01am, Monday, 10'th May 2021
Shares of Intra-Cellular Therapies (NASDAQ:ITCI) were unchanged after the company reported Q1 results. Quarterly Results Earnings per share rose 10.96% over the past year to ($0.65), which beat the es
Intra-Cellular Therapies Reports First Quarter 2021 Financial Results and Provides Corporate Update
07:30am, Monday, 10'th May 2021
CAPLYTA supplemental new drug applications (sNDAs) for the treatment of bipolar depression in adults as both monotherapy and adjunctive treatment with lithium or valproate have been accepted for revie
Intra-Cellular Therapies Announces FDA Acceptance of CAPLYTA® (lumateperone) sNDAs for the Treatment of Bipolar Depression
07:30am, Monday, 03'rd May 2021
NEW YORK, May 03, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nerv
Intra-Cellular: Substantial Unlocked Value In Caplyta Franchises
04:59pm, Friday, 23'rd Apr 2021
After its recent launch of Caplyta for schizophrenia, Intra-Cellular Therapies is poised to gain Caplyta label expansion for bipolar depression. Aside from three label expansions for Caplyta, the comp
Webcast to be Held Tuesday, May 4, 2021 at 2:00 p.m. EDT
Intra-Cellular Therapies Announces Board of Director Nominations in Advance of 2021 Annual Meeting
07:00am, Tuesday, 20'th Apr 2021
Board of Directors Nominates Sir Michael Rawlins GBE M.D., FRCP, FMedSci, Former Chairman of the UK's Medicines and Healthcare products Regulatory Agency (MHRA), as a New, Independent Director Board o
Intra-Cellular: Label Expansion PDUFA Up Ahead
09:39am, Sunday, 28'th Mar 2021
ITCI has one approved product targeting schizophrenia patients. It has an sNDA filed for a larger indication.
Intra-Cellular Therapies, Inc.'s (ITCI) CEO Sharon Mates on Q4 2020 Results - Earnings Call Transcript
02:47pm, Thursday, 25'th Feb 2021
Intra-Cellular Therapies, Inc.'s (ITCI) CEO Sharon Mates on Q4 2020 Results - Earnings Call Transcript
Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2020 Financial Results And Provides Corporate Update
07:30am, Thursday, 25'th Feb 2021
Successfully launched CAPLYTA ® (lumateperone) in late March 2020 and demonstrated strong commercial execution in the midst of COVID-19.
Intra-Cellular Therapies Discloses New Drug Candidate For Dementia Related Episodes
10:42am, Wednesday, 24'th Feb 2021
Intra-Cellular Therapies Inc (NASDAQ: ITCI) expands its pipeline with a new molecular entity, ITI-1284, a sublingually delivered deuterated form of lumateperone. ITI-1284 has been developed in co
Intra-Cellular Therapies Announces Expansion of its Pipeline with the Introduction of a New Molecular Entity, ITI-1284
07:30am, Wednesday, 24'th Feb 2021
ITI-1284 is a deuterated form of lumateperone delivered sublingually as an orally disintegrating tablet (ODT-SL). ITI-1284 ODT-SL may offer pharmacologic benefits and ease-of-use for patients, particu
Intra-Cellular Therapies Files US Application For Expanded Use Of Lumateperone In Bipolar Settings
01:15pm, Monday, 22'nd Feb 2021
Intra-Cellular Therapies Inc (NASDAQ: ITCI) submits CAPLYTA (lumateperone) supplemental marketing application to the FDA to treat depressive episodes associated with bipolar I or II disorder in ad
Patients with stable symptoms of schizophrenia were switched from previous antipsychotic medications with no dose titration to CAPLYTA 42 mg for a 6-week treatment duration, then switched back to prev
Do Options Traders Know Something About Intra-Cellular Therapies (ITCI) Stock We Don't?
09:47am, Wednesday, 06'th Jan 2021
Investors need to pay close attention to Intra-Cellular Therapies (ITCI) stock based on the movements in the options market lately.
Intra-Cellular Therapies to Present at the 39th Annual J.P. Morgan Healthcare Conference
08:00am, Tuesday, 05'th Jan 2021
NEW YORK, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervo
